Literature DB >> 432666

Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease.

W Lovenberg, R A Levine, D S Robinson, M Ebert, A C Williams, D B Calne.   

Abstract

A method for measuring hydroxylase cofactor activity in human cerebrospinal fluid is described. The hydroxylase cofactor content of cerebrsopinal fluid from Parkinsonian patients is approximately 50 percent that of normal subjects. A significant correlation between hydroxylase cofactor and the concentration of homovanillic acid in the cerebrospinal fluid was observed.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 432666     DOI： 10.1126/science.432666

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  26 in total

Review 1.  Neurodegeneration or neuroprotection: the pivotal role of astrocytes.

Authors:  Simon J R Heales; Amanda A J Lam; Andrew J Duncan; John M Land
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

2.  Protein expression in a Drosophila model of Parkinson's disease.

Authors:  Zhiyin Xun; Renã A Sowell; Thomas C Kaufman; David E Clemmer
Journal:  J Proteome Res       Date:  2007-01       Impact factor: 4.466

3.  Sepiapterin reductase expression is increased in Parkinson's disease brain tissue.

Authors:  Jennifer E Tobin; Jing Cui; Jemma B Wilk; Jeanne C Latourelle; Jason M Laramie; Ann C McKee; Mark Guttman; Samer Karamohamed; Anita L DeStefano; Richard H Myers
Journal:  Brain Res       Date:  2007-01-08       Impact factor: 3.252

4.  A model for hyperphenylalaninaemia due to tetrahydrobiopterin deficiency.

Authors:  R G Cotton
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

5.  Metabolomic Responses to Manganese Dose in SH-SY5Y Human Neuroblastoma Cells.

Authors:  Jolyn Fernandes; Joshua D Chandler; Ken H Liu; Karan Uppal; Li Hao; Xin Hu; Young-Mi Go; Dean P Jones
Journal:  Toxicol Sci       Date:  2019-05-01       Impact factor: 4.849

6.  Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.

Authors:  J A Wolff; L J Fisher; L Xu; H A Jinnah; P J Langlais; P M Iuvone; K L O'Malley; M B Rosenberg; S Shimohama; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.

Authors:  R J Mandel; K G Rendahl; S K Spratt; R O Snyder; L K Cohen; S E Leff
Journal:  J Neurosci       Date:  1998-06-01       Impact factor: 6.167

Review 8.  Tetrahydrobiopterin availability in Parkinson's and Alzheimer's disease; potential pathogenic mechanisms.

Authors:  Richard H Foxton; John M Land; Simon J R Heales
Journal:  Neurochem Res       Date:  2006-12-27       Impact factor: 3.996

9.  Effects of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on the dopaminergic and cholinergic receptors as evaluated by positron emission tomography in the Rhesus monkey.

Authors:  Y Tani; T Ishihara; T Kanai; T Ohno; J Andersson; A Lilja; G Antoni; K J Fasth; P Bjurling; G Westerberg
Journal:  J Neural Transm Gen Sect       Date:  1995

10.  Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson's disease.

Authors:  Hiroshi Ichinose; Ken-Ichi Inoue; Shinobu Arakawa; Yuki Watanabe; Hiroki Kurosaki; Shoko Koshiba; Eldbjorg Hustad; Masahiko Takada; Jan O Aasly
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.